Gastroenterology, Endoscopy ASC & Pathology Platform Architecture
Integrate clinical GI practices with accredited Endoscopy Surgery Centers (ASCs), in-source histology/pathology laboratory revenue, and capture premium 13x–16x platform exit valuations.
Gastroenterology (GI) remains a prized specialty in healthcare private equity due to non-discretionary procedural volume driven by federally mandated colorectal cancer screening guidelines (ACA Section 2713). A consolidated GI platform generates revenue from three distinct sources: professional clinical and endoscopic fees, Ambulatory Surgery Center (ASC) endoscopy facility fees, and in-house pathology/histology laboratory technical component margins. However, aggressive regulatory enforcement surrounding GI anesthesia joint ventures and pathology self-referrals requires meticulous legal structuring. Kompanie LLP guides private equity platforms in building integrated GI platforms that withstand OIG audit scrutiny while optimizing enterprise exit multiples.
Deliverables
- Turnkey Endoscopy ASC syndication agreement and operating charter.
- Stark-compliant In-House Histology Laboratory Management Agreement.
- Compliant Anesthesia Services Agreement eliminating kickback liabilities.
- Gastroenterology physician partner rollover equity and retirement buyout model.
Execution phases
- Stage 1: ASC & Pathology Regulatory Audit — Audit endoscopy ASC safe harbor compliance, review GI pathology billing (CPT 88305), and evaluate anesthesia company arrangements.
- Stage 2: Restructuring & Compliant Entity Design — Restructure anesthesia and pathology arrangements into Stark-compliant internal cost centers under the physician group practice charter.
- Stage 3: Regional Endoscopy Network Expansion — Execute tuck-in acquisitions of solo GI practices, migrate colonoscopies into platform ASCs, and negotiate commercial payer rate lifts.
Diligence red flags
- GI practice operating an exclusive anesthesia joint venture model where GI physicians capture anesthesia profits without bearing operational risk, triggering OIG kickback scrutiny.
- Pathology specimens referred to a captive lab entity that fails the Stark Law Same Building / Centralized Building test.
- Endoscopy ASC ownership diluted by non-performing retired physicians who fail the OIG One-Third procedure test.
- Commercial carriers downcoding screening colonoscopies turned diagnostic without proper appeals defense.
Frequently asked questions
Why are GI anesthesia joint ventures heavily scrutinized by the OIG?
The OIG issued specific fraud alerts warning against arrangements where gastroenterologists form shell anesthesia companies that contract out actual anesthesia services to CRNAs while retaining the anesthesia profits, classifying this as illegal remuneration for referrals.
How does in-sourcing histology pathology impact gastroenterology practice EBITDA?
In-sourcing biopsy slide processing (CPT 88305 technical component) captures $65 to $110 per specimen block that was previously lost to commercial reference labs, adding $180,000 to $350,000 in recurring EBITDA per gastroenterologist.